Eagle Pharmaceuticals, Inc.
EGRX
$1.90
-$0.07-3.55%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 64.65M | 66.31M | 60.70M | 65.90M | 74.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.65M | 66.31M | 60.70M | 65.90M | 74.14M |
| Cost of Revenue | 16.86M | 17.30M | 19.87M | 23.65M | 23.66M |
| Gross Profit | 47.79M | 49.01M | 40.83M | 42.25M | 50.47M |
| SG&A Expenses | 27.65M | 27.96M | 25.25M | 21.76M | 19.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.34M | 54.53M | 52.33M | 54.74M | 54.43M |
| Operating Income | 10.30M | 11.77M | 8.37M | 11.16M | 19.70M |
| Income Before Tax | 9.30M | 10.23M | 13.30M | -3.66M | -5.87M |
| Income Tax Expenses | 4.13M | 4.48M | 5.14M | 3.47M | 3.58M |
| Earnings from Continuing Operations | 5.16M | 5.75M | 8.17M | -7.13M | -9.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.16M | 5.75M | 8.17M | -7.13M | -9.45M |
| EBIT | 10.30M | 11.77M | 8.37M | 11.16M | 19.70M |
| EBITDA | 15.88M | 17.33M | 14.00M | 15.01M | 21.34M |
| EPS Basic | 0.39 | 0.44 | 0.63 | -0.54 | -0.74 |
| Normalized Basic EPS | 0.43 | 0.51 | 0.69 | 0.11 | 0.60 |
| EPS Diluted | 0.39 | 0.44 | 0.62 | -0.54 | -0.74 |
| Normalized Diluted EPS | 0.43 | 0.51 | 0.69 | 0.11 | 0.60 |
| Average Basic Shares Outstanding | 13.09M | 13.06M | 13.02M | 13.17M | 12.84M |
| Average Diluted Shares Outstanding | 13.15M | 13.15M | 13.12M | 13.17M | 12.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |